文献速递眼底病与葡萄膜炎

新生血管性年龄相关性黄斑变性治疗中断的后果

CONSEQUENCES OF LAPSES IN TREATMENT WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN ROUTINE CLINICAL PRACTICE.
PubMed 文献 · Retina · 2021-01-01

该回顾性研究评估了3304例接受抗VEGF治疗的nAMD患者中治疗中断≥3个月者的结局,与对照组比较发现中断后黄斑中心凹厚度显著增加且视力下降,恢复治疗后厚度正常化但视力下降至12个月未恢复。

要点

  • 治疗中断≥3个月者黄斑中心凹厚度显著增加,恢复治疗后正常化。
  • 中断后视力显著下降,且至12个月随访未恢复。
  • 治疗中断与更差的视力结局相关。

核心结论

  • nAMD患者治疗中断与更差结局相关,黄斑厚度恢复但视力下降不恢复。

研究设计与样本

  • 回顾性图表综述,评估3304例≥18岁接受抗VEGF治疗的nAMD患者,中断≥3个月者241例与对照组241例比较。

主要发现

  • 中断组与对照组基线视力相似(ETDRS 58.9±20.2 vs 59.2±20.1),中心凹厚度相似(252.4±63.2 µm vs 259.8±66.2 µm,P=0.21)。
  • 中断后中心凹厚度显著增加(279.4±86.9 µm vs 253.7±65.9 µm,P<0.01)。
  • 恢复治疗后中心凹厚度正常化(259.1±79 µm vs 246.8±57.6 µm,P=0.06)。
  • 中断后视力显著下降(ETDRS 52.9±23.6 vs 59.9±20.8,P<0.01),至12个月未恢复。

临床怎么用

  • 应重视nAMD抗VEGF治疗的连续性,避免治疗中断以保护视力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Evaluating outcomes in patients receiving intravitreal antivascular endothelial growth factor (VEGF) inhibitors for neovascular age-related macular degeneration whom experience a lapse in treatment. METHODS: A retrospective chart review evaluating 3,304 patients ≥18 years who experienced treatment lapses ≥3 months compared with control counterparts. Demographic information, macular thickness as measured by central subfield thickness, and visual acuity were collected at baseline, the first postlapse appointment, and at 3, 6, and 12 months after the lapse for the study group. RESULTS: Lapse (n = 241) and control patients (n = 241) had similar baseline visual acuity and central subfield thickness (Early Treatment Diabetic Retinopathy Study: 58.9 ± 20.2 [20/63] vs. 59.2 ± 20.1 [20/63]; central subfield thickness: 252.4 ± 63.2 µm vs. 259.8 ± 66.2 µm, P = 0.21). Analysis revealed that lapse patients experienced a significant increase in central subfield thickness after lapse when compared with controls (279.4 ± 86.9 µm vs. 253.7 ± 65.9 µm, P < 0.01), which normalized on resumption of treatment (259.1 ± 79 µm vs. 246.8 ± 57.6 µm, P = 0.06). Study patients also experienced loss in the visual acuity after lapse when compared with controls (52.9 ± 23.6 Early Treatment Diabetic Retinopathy Study [20/100] vs. 59.9 ± 20.8 [20/63] Early Treatment Diabetic Retinopathy Study, P < 0.01) that did not recover through 12 months of follow-up. CONCLUSION: Patients with neovascular age-related macular degeneration who have lapses in care are at risk for poorer outcomes. Although macular thickness normalizes on resumption of treatment, their decline in the visual acuity does not recover.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Greenlee TE, Wang VY, Kang H, et al. CONSEQUENCES OF LAPSES IN TREATMENT WITH VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN ROUTINE CLINICAL PRACTICE. Retina. 2021. PMID: 32658164. doi:10.1097/IAE.0000000000002888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。